A phase II study of weekly low-dose doxorubicin (6 to 12 mg/m2) showed it to be an effective, well-tolerated therapy in advanced breast cancer. Although most of the 34 patients studied had been clinically resistant to previous endocrine measures and/or other kinds of chemotherapy, had a median score of 60 on Karnofsky's index, and had predominantly visceral metastases, an objective response was obtained in 20 of 34 patients (four complete remissions, 16 partial remissions) for a median duration of 12+ months. Ten patients experienced no change in their condition for three to 12 months (median, six months). Eight of the 17 patients who had myelosuppression at the beginning of the study had an objective response lasting 4+ to 27+ months (median, 11 months). Eleven of the patients had previously received 500 or more mg/m2 of doxorubicin and were retreated with additional doses of doxorubicin (median cumulative dose, 800 mg/m2) without any clinical signs of toxicity.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Regulating tumor cells to awaken T cell antitumor function and enhance melanoma immunotherapy.
Biomaterials
May 2025
Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China.
Tumor cells transmit various immunosuppressive signals and induce a dysfunctional state in T cells, which essentially leads to immune escape and tumor progression. However, developing effective strategies to counteract the domestication of T cells by tumor cells remains a challenge. Here, we prepared pH-responsive lipid nanoparticles (NL/PLDs) co-loaded with PCSK9 shRNA, lonidamine (LND), and low-dose doxorubicin (DOX).
View Article and Find Full Text PDFNephroprotective effects of the soluble guanylyl cyclase stimulator, riociguat in doxorubicin-induced acute kidney injury in rats.
Toxicol Rep
December 2024
Department of Pharmacology and Clinical Pharmacy, College of Medicine and Health Sciences, Sultan Qaboos University, P.O. Box 35, Al Khod 123, Oman.
This study aimed to investigate the potential protective effects of riociguat, a soluble guanylyl cyclase (sGC) stimulator, on kidney function and structure in rats with acute kidney injury (AKI) induced by the chemotherapeutic drug doxorubicin (DX). Rats were subjected to a single intraperitoneal injection of DX (13.5 mg/kg) on the 5th day, either alone or in combination with low-dose riociguat (3 mg/kg/day), or high-dose riociguat (10 mg/kg/day) for 8 consecutive days.
View Article and Find Full Text PDFChelating drug-induced labile Zn with nanoparticle-encapsulated TPEN at low dose enhances lung cancer chemotherapy through inhibiting ABCB1.
iScience
November 2024
Medical Research Center, Henan China-Germany International Joint Laboratory of Tumor Immune Microenvironment and Disease, the First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan 450052, China.
Chemotherapy resistance is still a great challenge for clinical treatment of lung cancer. Here, we found that doxorubicin (DOX) induced an increase of labile Zn in lung cancer cells, and these labile Zn protected tumor cells against DOX cytotoxicity. Nanoparticles encapsulating N,N,N',N'-Tetrakis (2-pyridylmethyl)-ethylenediamine (TPEN) were then constructed to chelate labile Zn for tumor therapy.
View Article and Find Full Text PDFExtracellular vesicles from human breast cancer-resistant cells promote acquired drug resistance and pro-inflammatory macrophage response.
Front Immunol
October 2024
Department of Biochemistry and Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.
Introduction: Breast cancer is a significant public health problem around the world, ranking first in deaths due to cancer in females. The therapy to fight breast cancer involves different methods, including conventional chemotherapy. However, the acquired resistance that tumors develop during the treatment is still a central cause of cancer-associated deaths.
View Article and Find Full Text PDFDexamethasone-Sparing Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting in Highly and Moderately Emetogenic Chemotherapy: The SHEILD Study.
Cureus
September 2024
Medical Affairs, Zydus Lifesciences Ltd., Ahmedabad, IND.
Article Synopsis
- The study examines the effectiveness of a combination treatment of Generic Netupitant and Palonosetron (Nykron) with dexamethasone in preventing chemotherapy-induced nausea and vomiting (CINV) in patients undergoing highly and moderately emetogenic chemotherapy.
- It assesses outcomes like complete response and complete control of nausea/vomiting during both the acute (0-24 hours) and delayed (24-120 hours) phases after chemotherapy, gathering data from 372 cancer patients primarily diagnosed with breast or gastrointestinal cancers.
- Results indicate a high success rate for the regimen, with an overall response of 96.9%, suggesting it is an effective option for managing CINV while potentially reducing the need for higher
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!